MedPath
NMPA Approval

Indacaterol Acetate, Glycopyrronium Bromide and Mometasone Furoate Powder for Inhalation(I)

国药准字HJ20210033

May 19, 2021

Drug Information

茚达格莫吸入粉雾剂(Ⅰ)

吸入粉雾剂

每粒含醋酸茚达特罗150μg(以C₂₄H₂₈N₂O₃计 )、格隆溴铵50μg(以C₁₉H₂₈NO₃计)和糠酸莫米松80μg。

化学药品

May 19, 2021

May 18, 2026

Company Information

Applicant Company

Shop 6/207 Pacific Highway St Leonards NSW 2065 Australia

Manufacturing Company

novartis pharma stein ag;siegfried barbera, s.l.

Chemical Operations Schweiz Schaffhauserstrasse Stein, CH-4332, Switzerland;Ronda Santa Maria 158 BARBERA DEL VALLES BARCELONA, 08210 Spain

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

茚达格莫吸入粉雾剂(Ⅰ) - NMPA 批准文号 | MedPath